CHICAGO (October 6, 2009) - The legal landscape for life sciences companies continues to evolve at a faster pace. Two recent Federal Circuit Court of Appeals decisions have changed the rules for life science and pharmaceutical companies seeking DNA sequence patents. The American Civil Liberties Union (ACLU) also filed litigation aimed at declaring certain gene patents unconstitutional. The Federal Circuit’s Kubin and Gleave decisions, the ACLU litigation, and other developments in the patent law will likely transform the competitive landscape for biological drugs that involve patenting DNA and other molecules isolated from nature. McDermott Will & Emery LLP life science IP lawyers William Gaede and James Hill discussed these developments at a recent series of roundtables regularly held to keep McDermott clients abreast of the latest legal issues life science companies face.
Identifying such issues of vital importance to the life sciences industry, and providing sophisticated analysis of their implications, is the focus of an ongoing series of initiatives that McDermott Will & Emery LLP will sponsor over the next several months. Senior executives, general counsel and research leaders of pharmaceutical, biotechnology, and medical device companies, as well as university research organizations, will benefit from the experience that our lawyers, and key players from other organizations serving the life sciences sector, will share through in-person events and online webcasts that cover such issues as:
• The implications that health reform legislation, volatile credit market conditions and changing IP paradigms will have for life sciences deals and deal strategies.
• How personalized medicine’s genetic-based identification and testing, supported by President Obama and other top Administration officials, could transform the health care debate.
In addition to McDermott’s own events focused on vital life sciences concerns, we will be sponsors of, and panel and workshop participants at, such key upcoming industry events as AdvaMed 2009: The MedTech Conference, CBI’s Leadership Summit on Global Interactions with Healthcare Providers, the Mid-Atlantic Bio Conference, the JP Morgan Healthcare Conference and the CBI Pharmaceutical Compliance Congress.
Click here for more information on the full slate of events and topics that are available. You will find a wide range of opportunities that can help life sciences organizations seize strategic advantage today – and secure it for tomorrow.